Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial

Table 3

The mean score of SF-36, SF-36PH, and SF-36MH. Intention-to-treat population.

	Group	Mean baseline (±s.d.)		Mean week 2 (±s.d.)	Mean CBTW2 (±s.d.)	Mean week 4 (±s.d.)	Mean C2WAT (±s.d.)
SF-36	Control ()	76.3 (5.5)	0.95	85.8 (5.6)	9.5 (6.1)	79.9 (7)	5.9 (3.7)
	Intervention ()	76.8 (6)		92.3 (4.8)	15.6 (6.8)	90.3 (5.2)	2 (2.9)
SF-36PH	Control ()	74.5 (6.7)	0.47	84.9 (6.2)	10.7 (6.4)	78.8 (7.4)	6 (4.1)
	Intervention ()	75.7 (8)		92.1 (5)	16.4 (8.9)	90.5 (6)	1.7 (2)
SF-36MH	Control ()	76.2 (7)	0.90	86.6 (5.9)	11.1 (6.2)	80.8 (6.8)	4.7 (4.5)
	Intervention ()	76.4 (6.9)		92.4 (5.6)	16 (7.2)	91.4 (4.7)	1.9 (2.5)

: value; SF-36: 36-Item Short-Form Health Survey; SF-36PH: 36-Item Short-Form Health Survey physical health; SF-36MH: 36-Item Short-Form Health Survey mental health; mean CBTW2: mean change baseline to week 2; mean C2WAT: mean change 2 week after treatment; intervention: herbal medicine; control: hyoscine. , intervention vs. control.